Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TCRX Stock Forecast 2026-2027
$1.13
Current Price
$64.13M
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to TCRX Price Targets
+519.5%
To High Target of $7.00
+431.0%
To Median Target of $6.00
+342.5%
To Low Target of $5.00
TCRX Price Momentum
-3.4%
1 Week Change
+25.6%
1 Month Change
-52.9%
1 Year Change
+13.0%
Year-to-Date Change
-57.7%
From 52W High of $2.67
+28.1%
From 52W Low of $0.88
📊 TOP ANALYST CALLS
Did TCRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if TScan is one of their latest high-conviction picks.
Latest TCRX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, TCRX has a bullish consensus with a median price target of $6.00 (ranging from $5.00 to $7.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.13, the median forecast implies a 431.0% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andres Y. Maldonado at HC Wainwright & Co., projecting a 519.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TCRX Analyst Ratings
5
Buy
2
Hold
0
Sell
TCRX Price Target Range
Low
$5.00
Average
$6.00
High
$7.00
Current: $1.13
Latest TCRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TCRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Maintains | $7.00 |
| Nov 4, 2025 | Needham | Gil Blum | Buy | Maintains | $6.00 |
| Nov 4, 2025 | BTIG | Justin Zelin | Neutral | Downgrade | $N/A |
| May 7, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $10.00 |
| Apr 8, 2025 | Needham | Gil Blum | Buy | Reiterates | $9.00 |
| Mar 14, 2025 | Morgan Stanley | Maxwell Skor | Overweight | Assumes | $10.00 |
| Mar 7, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $3.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Mar 5, 2025 | Needham | Gil Blum | Buy | Maintains | $9.00 |
| Dec 11, 2024 | Needham | Gil Blum | Buy | Reiterates | $11.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Nov 12, 2024 | Needham | Gil Blum | Buy | Reiterates | $11.00 |
| Nov 6, 2024 | Needham | Gil Blum | Buy | Reiterates | $11.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| Aug 13, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $10.00 |
| Aug 12, 2024 | Needham | Gil Blum | Buy | Reiterates | $11.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
| May 16, 2024 | BTIG | Justin Zelin | Buy | Initiates | $12.00 |
| May 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $15.00 |
TScan Therapeutics Inc. (TCRX) Competitors
The following stocks are similar to TScan based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TScan Therapeutics Inc. (TCRX) Financial Data
TScan Therapeutics Inc. has a market capitalization of $64.13M with a P/E ratio of -1.0x. The company generates $8.42M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +139.4% quarter-over-quarter, while maintaining an operating margin of -1,475.6% and return on equity of -76.4%.
Valuation Metrics
Market Cap
$64.13M
Enterprise Value
$-24,705,768
P/E Ratio
-1.0x
PEG Ratio
-0.1x
Price/Sales
7.6x
Growth & Margins
Revenue Growth (YoY)
+139.4%
Gross Margin
N/A
Operating Margin
-1,475.6%
Net Margin
0.0%
EPS Growth
+139.4%
Financial Health
Cash/Price Ratio
+287.6%
Current Ratio
6.4x
Debt/Equity
66.4x
ROE
-76.4%
ROA
-30.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
TScan Therapeutics Inc. (TCRX) Business Model
About TScan Therapeutics Inc.
What They Do
Develops T-cell therapies for cancer treatment.
Business Model
The company operates as a clinical-stage biotechnology firm, generating revenue through the development and commercialization of T-cell receptor-engineered T cell (TCR-T) therapies. It focuses on engineering T cells to target and eliminate tumor cells, aiming to meet the unmet medical needs in oncology and immunotherapy.
Additional Information
TScan Therapeutics targets various malignancies, including solid tumors and hematological cancers, and is involved in extensive research and clinical trials. Headquartered in Waltham, Massachusetts, the company contributes significantly to the advancement of immune-oncology therapies and T-cell engineering.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
146
CEO
Dr. Gavin MacBeath Ph.D.
Country
United States
IPO Year
2017
Website
www.tscan.comTScan Therapeutics Inc. (TCRX) Latest News & Analysis
Latest News
Quick Summary
TScan Therapeutics (Nasdaq: TCRX) will host a virtual KOL event on December 8 to discuss updated data from the ALLOHA™ Phase 1 trial and market opportunities for its heme program.
Why It Matters
TScan Therapeutics' KOL event on updated trial data could influence stock performance and investor sentiment, especially regarding its cancer treatment pipeline and market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2 months ago
Quick Summary
TScan Therapeutics reached an agreement with the FDA on TSC-101 study design and will present Phase 1 heme trial data at the ASH Annual Meeting. They plan to prioritize heme program development and have funding until mid-2027.
Why It Matters
The agreement with the FDA on study design and ongoing funding through 2027 enhances TScan Therapeutics' growth potential, positively influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TScan Therapeutics reported a quarterly loss of $0.28 per share, better than the expected loss of $0.35, but worse than a loss of $0.25 per share from the same quarter last year.
Why It Matters
TScan's smaller-than-expected quarterly loss signals better-than-anticipated financial performance, potentially boosting investor confidence and impacting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
The company reached a favorable Phase I meeting with the FDA for TSC-101, paused solid tumor patient enrollment to focus on hematology, and plans a data readout in Q1 2026. A workforce reduction extends cash runway to H2 2027.
Why It Matters
The positive FDA meeting and strategic focus on heme development suggest potential for future approvals and extended cash runway, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2 months ago
Quick Summary
TScan Therapeutics (Nasdaq: TCRX) will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 12, 2025, at 10:00 a.m. ET in Boston.
Why It Matters
TScan Therapeutics' participation in a healthcare conference highlights its commitment to innovation and visibility in the biotech sector, potentially attracting investor interest and influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Novel targets for T cell-driven autoimmune disorders have been discovered, with initial findings set to be presented at ACR Convergence 2025.
Why It Matters
Novel targets for T cell-driven autoimmune disorders could lead to new therapies, potentially boosting the market value of related biotech companies and impacting investor sentiment in the sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TCRX Stock
What is TScan Therapeutics Inc.'s (TCRX) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, TScan Therapeutics Inc. (TCRX) has a median price target of $6.00. The highest price target is $7.00 and the lowest is $5.00.
Is TCRX stock a good investment in 2026?
According to current analyst ratings, TCRX has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TCRX stock?
Wall Street analysts predict TCRX stock could reach $6.00 in the next 12 months. This represents a 431.0% increase from the current price of $1.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is TScan Therapeutics Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, generating revenue through the development and commercialization of T-cell receptor-engineered T cell (TCR-T) therapies. It focuses on engineering T cells to target and eliminate tumor cells, aiming to meet the unmet medical needs in oncology and immunotherapy.
What is the highest forecasted price for TCRX TScan Therapeutics Inc.?
The highest price target for TCRX is $7.00 from Andres Y. Maldonado at HC Wainwright & Co., which represents a 519.5% increase from the current price of $1.13.
What is the lowest forecasted price for TCRX TScan Therapeutics Inc.?
The lowest price target for TCRX is $5.00 from at , which represents a 342.5% increase from the current price of $1.13.
What is the overall TCRX consensus from analysts for TScan Therapeutics Inc.?
The overall analyst consensus for TCRX is bullish. Out of 9 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are TCRX stock price projections?
Stock price projections, including those for TScan Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 2:59 AM UTC